Endo Pharmaceuticals agreed to pull Opana ER, its abuse-deterrent , extended-release formulation of the powerful painkiller oxymorphone, off the market after urging by the Food and Drug Administration (FDA) to stop selling the drug because it not only aggravated the opioid epidemic, it also put abusers at risk of serious health problems. Endo obliged reluctantly, saying it “continues to believe in the safety, efficacy and favorable benefit-risk profile” of the drug. “Nevertheless, after careful consideration and consultation with the FDA following the FDA’s June 2017 withdrawal request, the company has decided to voluntarily remove Opana ER from the market.” The ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.